GAMMA Investing LLC Increases Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

GAMMA Investing LLC increased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 18.9% in the 4th quarter, Holdings Channel reports. The fund owned 1,383 shares of the company’s stock after buying an additional 220 shares during the quarter. GAMMA Investing LLC’s holdings in Prestige Consumer Healthcare were worth $108,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quest Partners LLC grew its position in Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after acquiring an additional 424 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after buying an additional 433 shares during the period. nVerses Capital LLC grew its stake in shares of Prestige Consumer Healthcare by 200.0% during the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after buying an additional 400 shares during the last quarter. Huntington National Bank increased its holdings in shares of Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after buying an additional 181 shares during the period. Finally, International Assets Investment Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 7,112.5% in the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after acquiring an additional 1,138 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the sale, the executive vice president now directly owns 18,365 shares in the company, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on PBH shares. Jefferies Financial Group restated a “hold” rating and set a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson restated a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.25.

Prestige Consumer Healthcare Stock Down 0.6 %

NYSE PBH opened at $73.96 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The stock has a market capitalization of $3.65 billion, a PE ratio of 18.00, a PEG ratio of 2.32 and a beta of 0.51. Prestige Consumer Healthcare Inc. has a 1 year low of $58.22 and a 1 year high of $86.36. The business’s 50-day moving average is $80.56 and its 200 day moving average is $74.21.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.09. The company had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Prestige Consumer Healthcare’s quarterly revenue was down .9% on a year-over-year basis. During the same period last year, the firm earned $1.07 earnings per share. Sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.